News & Updates

The investigational allogeneic cell therapy deramiocel helps mitigate the progression of upper limb disease in young patients with Duchenne muscular dystrophy (DMD), as shown in the pivotal phase 3 HOPE-3 study.

Inhibition of the protein kinase C iota (PKCι) with auranofin and sirolimus does not provide antineoplastic effects in patients with recurrent high-grade serous ovarian cancer, reports a phase II study.

High-dose influenza vaccination is associated with a reduced risk of hospitalization for pneumonia or influenza in older adults, regardless of immunosuppression status, according to a prespecified pooled analysis of the FLUNITY-HD study presented at ESCMID Global 2026.

Nitrofurantoin performs better than single-dose fosfomycin in the treatment of uncomplicated urinary tract infections (UTIs) in women in the primary care setting, according to the SCOUT trial.

First-line treatment with immune checkpoint inhibitors (ICIs) is safe and effective in patients with extended stage (ES) small-cell lung cancer (SCLC), but its use as second-line agent is not recommended, according to a study.

The 5-year data from the phase III IMCgp100-202 study demonstrate durable, long-term overall survival (OS) benefit with the novel agent tebentafusp—a first-in-class, bispecific, soluble T-cell receptor (TCR) therapeutic—in individuals with previously untreated metastatic uveal melanoma (UM).

New drug applications approved by US FDA as of 16-30 April 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.